Latest news

• Daily Brief: Europe reverses stance on Puma’s neratinib, Pfizer expands healthcare hubs, AbbVie and Calico boosts age-related diseases collab

  Daily Brief: Europe reverses stance on Puma’ s neratinib, Pfizer expands healthcare hubs, AbbVie and Calico boosts age-related diseases collab. ... The EMA's Committee for Medicinal Products for Human Use (CHMP) is set to approve the use of Puma

• Pfizer’s leukaemia drug Mylotarg backed for use in EU

  There was worse news for Puma Biotechnology - which has its application to market Nerlyx (neratinib) for breast cancer turned down - and also Pfizer whose application to extend the indications of Sutent

• Roche trumpets APHINITY data, but did it hit the mark?

  The results of the APHINITY trial could present an opportunity to US biotech Puma, which won a positive recommendation from an FDA advisory committee for its neratinib candidate in post-surgery ... In trials, neratinib achieved a 33% reduction in the

• FDA panel backs Puma's breast cancer drug, with reservations

  US biotech Puma took a step closer to approval of its breast cancer therapy neratinib after an FDA advisory committee voted in favour of the drug. ... A number of analysts have suggested neratinib may be approved only in patients with hormone

• Oncology bias in pharma deals

  Pfizer has licensed the worldwide commercial rights of Neratinib, a phase II pan-HER inhibitor (potent irreversible tyrosine kinase inhibitor) in the neoadjuvant, adjuvant and advanced settings in HER2/ErbB2 positive ... 2 ##. Pfizer/Puma Biotechnology ##